Delayed/slow graft function is the most common complication after kidney transplantation with an incidence over 20% and is the result of ischemia-reperfusion injury. The increased use of marginal kidney grafts to palliate the organ shortage is leading to a continued rise in the incidence of delayed/slow graft function. Delayed/slow graft function, however, is associated with an increased risk of acute rejection and graft failure. There are currently no clinically accepted biomarkers and no specific treatments for delayed/slow graft function. Regulatory T cells are protective in ischemia-reperfusion injury and rejection by suppressing pathologic immune responses. We hypothesize that the pre-transplant measurement of highly suppressive regulatory T cell is an accurate biomarker for delayed/slow graft function and its immunologic consequences. Ultimately, marginal kidney graft allocation could be directed to regulatory T cell-robust recipients and regulatory T cell-directed therapies could decrease marginal kidney graft discards without increasing delayed/slow graft function or impacting outcomes.
Study Type
OBSERVATIONAL
Enrollment
180
Circulating highly suppressive Treg measurement
Loma Linda University Health Transplantation Institute
San Bernardino, California, United States
Saint Louis University
St Louis, Missouri, United States
Delayed graft function
Delayed graft function defined as dialysis requirement within the first week after kidney transplant
Time frame: 1 week
Slow graft function
Slow graft function defined as a serum creatinine drop of less than 20% in the first 24 hours after kidney transplant
Time frame: 24 hours
Acute rejection
Kidney allograft biopsy-proven acute rejection according to Banff criteria
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.